Eton Pharmaceuticals: FDA extends PDUFA date for NDA for ET-400 to 5/28
Eton Pharmaceuticals (ETON) announced that the U.S. FDA has extended the Prescription Drug User Fee Act goal date for the New Drug Application ...
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug ...
FDA extends target action date for Eton's ET-400
Eton Pharmaceuticals (NASDAQ:ETON) said the FDA has extended the target action date for its market application for ET-400 to May 28 from Feb. 28. The company said it has been notified that the FDA ...
One year after drug approval, X4 Pharmaceuticals cuts staff
Nearly one year after winning an FDA drug approval to treat an ultra-rare disease, X4 Pharmaceuticals is making layoffs that ...
Amgen Inc. (NASDAQ:AMGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations were $5.04. Operator: My name is Julienne, and I will be your conference ...
Philip Morris CEO: We're pleased with FDA approval of Zyn
Jacek Olczak, Philip Morris International CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings.
FDA approves Lipella's oral treatment access program
PITTSBURGH - Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a biotech firm specializing in novel therapies for medical conditions lacking adequate treatments, has received FDA approval for an Expanded ...
RenovoRx launches public stock offering
MOUNTAIN VIEW, Calif. - RenovoRx , Inc. (NASDAQ:RNXT), a $35.7 million market cap developer of targeted oncology therapies, has initiated an underwritten public offering of its common stock and ...
manilatimes11h
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
LP-310 is an innovative, localized therapy formulated to provide targeted relief for OLP patients while minimizing systemic exposure. Oral lichen planus is a chronic inflammatory condition affecting ...
Lipocine plans phase 3 study for postpartum depression drug
SALT LAKE CITY - Lipocine Inc. (NASDAQ: NASDAQ:LPCN), a biopharmaceutical company with a market capitalization of approximately $24 million, announced today that it will conduct a phase 3 safety and ...
Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now
We recently compiled a list of the 10 Best Rebound Stocks To Invest In Now. In this article, we are going to take a look at ...
Citius Pharma's LYMPHIR gains permanent J-code for billing
Inc. and its subsidiary Citius Oncology, Inc. have announced the assignment of a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for their drug LYMPHIR by the Centers for Medicare & ...